Moderna Inc MRNA is trading higher Monday morning amid renewed COVID-19 concerns.
The recent spread of the COVID-19 Delta variant is a major concern. Delta first appeared in India at the end of 2020. The highly contagious COVID-19 variant surfaced in the United States in March and is now the dominant strain.
It was announced that Moderna would be added to the S&P 500 Index last week. The stock surged 10% following the news.
Last Thursday, Jefferies analyst Michael Yee maintained Moderna with a Hold rating and raised the price target from $170 to $250.
Moderna is set to report its second-quarter financial results on Aug. 5.
Price Action: Moderna is making a new 52-week high in trading today.
At last check Monday, the stock was up 6.56% at $305.19.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.